Governance
Investors

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

Jun 01 2023
,

Philogen Announces Clinical Trial Collaboration with MSD

Nidlegy™_CTCSA_Merck_Press_Release_ENG
May 31 2023
, ,

Philogen kindly invites you to attend a virtual briefing for analysts on 5 June 2023 to discuss the Company’s latest updates.

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, and Dr. Emanuele Puca, Head of Investor Relations, will host a 1-hour live...
May 30 2023
, ,

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand (Price Sensitive)

More details
May 30 2023
, ,

Sun Pharma e Philogen stipulano un Accordo di commercializzazione, Licenza e Fornitura in esclusiva per il prodotto innovativo Nidlegy™ in Europa, Australia e Nuova Zelanda (Price Sensitive)

More details
May 29 2023
, ,

29 maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details
May 26 2023
, ,

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

230524_Philogen_STM_Press_Release
May 24 2023
, ,

Deposito del Verbale dell’Assemblea degli Azionisti

more details
May 22 2023
, ,

22 maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details
May 15 2023
, ,

Philogen S.p.A. nomina Mediobanca – Banca di Credito Finanziario S.p.A., quale intermediario incaricato dell’esecuzione del programma di acquisto di azioni proprie

More details
May 11 2023
, ,

The Board of Directors approves the Net Financial Position for the First Quarter of 2023

more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions